case_images: PMC3461627_01
case_images: Right axillary node biopsy demonstrating diffuse large B-cell lymphoma.
case_images: CRIM.ONCMED2012-685919.001.jpg
case_images: PMC3461627_01_CRIM.ONCMED2012-685919.001.jpg
case_images: fig1
case_images: She underwent excisional biopsy of a right axillary node which demonstrated DLBCL (Figure 1).
case_images: Right breast ductal carcinoma in situ.
case_images: CRIM.ONCMED2012-685919.002.jpg
case_images: PMC3461627_01_CRIM.ONCMED2012-685919.002.jpg
case_images: fig2
case_images: Ultrasound-guided needle core biopsy of the breast lesions demonstrated ductal carcinoma in situ (DCIS) in the right breast (Figure 2), and estrogen and progesterone receptor positive, HER2 receptor negative infiltrating ductal carcinoma in the left breast (Figure 3).
case_images: Left breast infiltrating ductal carcinoma.
case_images: CRIM.ONCMED2012-685919.003.jpg
case_images: PMC3461627_01_CRIM.ONCMED2012-685919.003.jpg
case_images: fig3
case_images: Ultrasound-guided needle core biopsy of the breast lesions demonstrated ductal carcinoma in situ (DCIS) in the right breast (Figure 2), and estrogen and progesterone receptor positive, HER2 receptor negative infiltrating ductal carcinoma in the left breast (Figure 3).
case_images: Dose volume histogram showing coverage of breast tumor bed (red) with standard breast tangents and incidental ipsilateral axillary coverage (purple).
case_images: CRIM.ONCMED2012-685919.004.jpg
case_images: PMC3461627_01_CRIM.ONCMED2012-685919.004.jpg
case_images: fig4
case_images: Completion of her breast conservation therapy with standard breast tangent fields allowed for incidental inclusion of levels I and II of the axilla in the treatment field with 88% of the right axilla receiving 3,000 cGy or more (Figure 4).